Company Encyclopedia
View More
name
TY PHAR.
002728.SZ
Teyi Pharmaceutical Group Co.,Ltd engages in the research and development, production, and sale of Chinese patent medicines, pharmaceutical preparations, raw materials, and products in the People’s Republic of China. The company provides cough and phlegm, kidney, anti- infection, cardiovascular and cerebrovascular, and digestive system drugs, as well as pediatrics, dermatology, tuberculosis, respiratory, rheumatology, nephrology, and endocrinology medicines. Its chemical raw materials and products include aluminum carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc.The company was formerly known as Guangdong Taicheng Pharmaceutical Co., Ltd. and changed its name to Teyi Pharmaceutical Group Co.,Ltd in November 2016.
3.159 T
002728.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking46/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.50%C
    • Profit Margin8.63%B
    • Gross Margin48.89%B
  • Growth ScoreB
    • Revenue YoY18.84%B
    • Net Profit YoY12.73%C
    • Total Assets YoY-10.86%E
    • Net Assets YoY3.52%C
  • Cash ScoreB
    • Cash Flow Margin1159.36%B
    • OCF YoY18.84%B
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreA
    • Gearing Ratio18.81%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TY PHAR. released its performance for the first three quarters, with a net profit attributable to the parent company of 65.2171 million yuan, a year-on-year increase of 985.18%

    According to the Zhitong Finance APP, TY PHAR. released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 692 million yuan, a year-on-year increase of 51.86%. The net profit attributable to shareholders of the listed company was 65.2171 million yuan, a year-on-year increase of 985.18%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 62.8097 million yuan, a year-on-year increase of 2508.06%

    Zhitong·
    SZ
    002728
    -1.66%
    Zhitong·
    SZ
    002728
    -1.66%

    TY PHAR.: Abnormal fluctuations in stock trading

    TY PHAR. announced that the closing price of the company's stock has increased by more than 20% cumulatively over three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. After verification, the company's operations are normal, and there have been no significant changes in the disclosed operating conditions and internal and external environments. The previously disclosed information does not need to be corrected or supplemented. The company has not found any undisclosed significant information in recent public media reports that may affect the stock price, and there have been no transactions involving the company's stock by the controlling shareholder and actual controller during the period of abnormal fluctuation

    Zhitong·
    SZ
    002728
    -1.66%
    Zhitong·
    SZ
    002728
    -1.66%

    The influenza sector has risen again, with CISEN and TY PHAR. both hitting the daily limit

    The influenza sector has risen again, with CISEN and TY PHAR. both hitting the daily limit, while Harbin Three Alliance and Guangji Pharmaceutical previously locked their boards, and Hendi Pharmaceutical and Duoyi Pharmaceutical rose over 10%

    Zhitong·
    SH
    603367
    +0.83%
    SZ
    002728
    -1.66%
    Zhitong·
    SH
    603367
    +0.83%
    SZ
    002728
    -1.66%

    TY PHAR. released its performance for the first half of the year, with a net profit attributable to the parent company of 38.077 million yuan, an increase of 1313.23%

    TY PHAR. released its semi-annual report for 2025, with operating revenue of 491 million yuan, a year-on-year increase of 56.54%. The net profit attributable to the parent company was 38.077 million yuan, a year-on-year increase of 1313.23%. The net profit after deducting non-recurring gains and losses was 38.0853 million yuan, a year-on-year increase of 6095.52%. The basic earnings per share were 0.08 yuan

    Zhitong·
    SZ
    002728
    -1.66%
    Zhitong·
    SZ
    002728
    -1.66%

    TY PHAR. : The acetaminophen tablets produced and sold by the company can be used for symptoms related to Chikungunya fever

    TY PHAR. stated on the interactive platform that according to the "Diagnosis and Treatment Plan for Chikungunya Fever" issued by the National Health Commission and the National Administration of Traditional Chinese Medicine, the acetaminophen tablets produced by the company can be used for symptoms of chikungunya fever, such as high fever and joint pain. The company promises to ensure the supply of medicines based on market demand, ensuring the quality and production capacity of medicines to fulfill its social responsibility

    Zhitong·
    SZ
    002728
    -1.66%
    Zhitong·
    SZ
    002728
    -1.66%
    © 2025 Longbridge｜Disclaimer